Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 3OTHER_GOV 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

apatinib 3pembrolizumab 2Poly(ADP-ribose) Polymerase Inhibitors 2Hyperthermic Intraperitoneal Chemotherapy 2Bevacizumab 2taxane 1olaparib 1lenvatinib 1fludarabine 1cediranib 1Whole Genome Sequencing 1Valproic Acid 1Tranexamic Acid 1Tai Ji 1Surgical Procedures, Operative 1Sequence Analysis, RNA 1Saline Solution 1Radiation 1Qigong 1Propranolol 1Positron Emission Tomography Computed Tomography 1Population Groups 1Platinum 1Paclitaxel 1Neoadjuvant Therapy 1Interleukin-2 1Indocyanine Green 1Immunohistochemistry 1Hydralazine 1Gene Expression 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Ovarian Neoplasms × Poly(ADP-ribose) Polymerase Inhibitors × Clear all
NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

N.N. Alexandrov National Cancer Centre

Phase 2/3 Recruiting
120 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05200260 2025-02-10

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Shanghai Gynecologic Oncology Group

Phase 2 Recruiting
220 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡